MX2021002970A - Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. - Google Patents
Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.Info
- Publication number
- MX2021002970A MX2021002970A MX2021002970A MX2021002970A MX2021002970A MX 2021002970 A MX2021002970 A MX 2021002970A MX 2021002970 A MX2021002970 A MX 2021002970A MX 2021002970 A MX2021002970 A MX 2021002970A MX 2021002970 A MX2021002970 A MX 2021002970A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- associated antigen
- proteins binding
- binding nkg2d
- nkg2d
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Se describen proteínas de unión multiespecíficas que se unen al receptor NKG2D, CD16 y un antígeno asociado a tumores, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762555110P | 2017-09-07 | 2017-09-07 | |
US201762566824P | 2017-10-02 | 2017-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002970A true MX2021002970A (es) | 2021-05-12 |
Family
ID=65634405
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002626A MX2020002626A (es) | 2017-09-07 | 2018-09-07 | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores. |
MX2021002970A MX2021002970A (es) | 2017-09-07 | 2020-03-06 | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002626A MX2020002626A (es) | 2017-09-07 | 2018-09-07 | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumores. |
Country Status (13)
Country | Link |
---|---|
US (3) | US20200277383A1 (es) |
EP (2) | EP3925976A1 (es) |
JP (3) | JP7431392B2 (es) |
KR (2) | KR20200044957A (es) |
CN (2) | CN113004417A (es) |
AU (2) | AU2018329937A1 (es) |
BR (1) | BR112020004489A2 (es) |
CA (2) | CA3112984A1 (es) |
IL (2) | IL273067A (es) |
MX (2) | MX2020002626A (es) |
RU (1) | RU2021110369A (es) |
SG (2) | SG10202102502VA (es) |
WO (1) | WO2019051308A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
CA3235295A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
CA3090236A1 (en) * | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
CN113286808A (zh) | 2018-10-23 | 2021-08-20 | 蜻蜓疗法股份有限公司 | 异二聚体Fc融合蛋白 |
WO2021087245A1 (en) * | 2019-10-30 | 2021-05-06 | The Texas A&M University System | Protease switch for dual targets chimeric antigen receptor t cell therapy |
JP2023522972A (ja) * | 2020-04-22 | 2023-06-01 | ドラゴンフライ セラピューティクス, インコーポレイテッド | ヘテロ二量体Fc融合タンパク質のための製剤、投薬量レジメン、及び製造工程 |
EP4213888A1 (en) * | 2020-09-17 | 2023-07-26 | Agensys, Inc. | Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
CN113563474B (zh) * | 2021-06-11 | 2023-05-02 | 广州医科大学附属第三医院(广州重症孕产妇救治中心、广州柔济医院) | EpCAM-CD16-NKG2D三特异性抗体及其应用 |
AU2022328753A1 (en) * | 2021-08-20 | 2024-01-25 | Tallac Therapeutics, Inc. | Nectin-4 antibodies and conjugates |
AU2022358500A1 (en) * | 2021-09-29 | 2024-04-04 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and baff-r |
KR20230060546A (ko) * | 2021-10-22 | 2023-05-04 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
WO2024026253A1 (en) * | 2022-07-25 | 2024-02-01 | Agensys, Inc. | Methods for treating patients with locally advanced or metastatic urothelial cancer with antibody drug conjugates (adc) that bind 191p4d12 proteins in combination with pembrolizumab |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003111595A (ja) * | 2001-06-25 | 2003-04-15 | Kyogo Ito | 腫瘍抗原 |
CN1812999A (zh) * | 2003-05-31 | 2006-08-02 | 麦克罗梅特股份公司 | 包含EpCAM特异构建体的药物组合物 |
JP2009500346A (ja) | 2005-06-29 | 2009-01-08 | ユニバーシティー・オブ・マイアミ | 癌処置用の抗体−免疫細胞リガンド融合タンパク質 |
EA017491B1 (ru) | 2005-12-08 | 2012-12-28 | Медарекс, Инк. | Человеческие моноклональные антитела к фукозил-gm1 и способы применения антифукозил-gm1 антител |
WO2010067487A1 (en) | 2008-12-12 | 2010-06-17 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
CN102448486A (zh) | 2009-03-06 | 2012-05-09 | 艾更斯司股份有限公司 | 结合于24p4c12蛋白的抗体药物偶联物(adc) |
WO2011003780A1 (en) * | 2009-07-06 | 2011-01-13 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
TW202344270A (zh) | 2010-09-29 | 2023-11-16 | 美商艾澤西公司 | 與191p4d12蛋白結合之抗體藥物共軛物(adc) |
CN107936121B (zh) * | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
JP6571527B2 (ja) | 2012-11-21 | 2019-09-04 | ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドWuhan Yzy Biopharma Co., Ltd. | 二重特異性抗体 |
WO2014124326A1 (en) * | 2013-02-08 | 2014-08-14 | Stem Centrx, Inc. | Novel multispecific constructs |
PT3021869T (pt) * | 2013-07-16 | 2020-09-10 | Hoffmann La Roche | Métodos de tratamento do cancro com antagonistas da ligação ao eixo pd-1 e inibidores do tigit |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
MX2016008098A (es) * | 2013-12-20 | 2017-01-11 | Hoffmann La Roche | Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso. |
WO2015095972A1 (en) | 2013-12-23 | 2015-07-02 | The Centre For Drug Research And Development | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
JP2018503399A (ja) | 2015-01-14 | 2018-02-08 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | 多特異性免疫調節抗原結合構築物 |
AU2016219785B2 (en) | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
US10675357B2 (en) | 2015-09-09 | 2020-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to nectin-4 and uses thereof |
-
2018
- 2018-09-07 WO PCT/US2018/050073 patent/WO2019051308A1/en active Application Filing
- 2018-09-07 RU RU2021110369A patent/RU2021110369A/ru unknown
- 2018-09-07 CA CA3112984A patent/CA3112984A1/en active Pending
- 2018-09-07 CN CN202110251101.6A patent/CN113004417A/zh active Pending
- 2018-09-07 EP EP21164073.5A patent/EP3925976A1/en not_active Withdrawn
- 2018-09-07 MX MX2020002626A patent/MX2020002626A/es unknown
- 2018-09-07 EP EP18853095.0A patent/EP3679071A4/en active Pending
- 2018-09-07 BR BR112020004489-0A patent/BR112020004489A2/pt unknown
- 2018-09-07 KR KR1020207009780A patent/KR20200044957A/ko not_active Application Discontinuation
- 2018-09-07 JP JP2020513796A patent/JP7431392B2/ja active Active
- 2018-09-07 KR KR1020217007213A patent/KR20210030503A/ko not_active Application Discontinuation
- 2018-09-07 SG SG10202102502VA patent/SG10202102502VA/en unknown
- 2018-09-07 SG SG11202001930QA patent/SG11202001930QA/en unknown
- 2018-09-07 US US16/644,585 patent/US20200277383A1/en not_active Abandoned
- 2018-09-07 CN CN201880071464.8A patent/CN111315782A/zh active Pending
- 2018-09-07 AU AU2018329937A patent/AU2018329937A1/en active Pending
- 2018-09-07 CA CA3074840A patent/CA3074840A1/en active Pending
-
2020
- 2020-03-04 IL IL273067A patent/IL273067A/en unknown
- 2020-03-06 MX MX2021002970A patent/MX2021002970A/es unknown
-
2021
- 2021-03-02 US US17/190,155 patent/US20210292420A1/en not_active Abandoned
- 2021-03-08 IL IL281323A patent/IL281323A/en unknown
- 2021-03-09 JP JP2021037490A patent/JP2021098733A/ja active Pending
- 2021-03-09 AU AU2021201494A patent/AU2021201494A1/en active Pending
-
2023
- 2023-02-13 US US18/108,961 patent/US20230357409A1/en active Pending
- 2023-08-14 JP JP2023132099A patent/JP2023166409A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200044957A (ko) | 2020-04-29 |
US20230357409A1 (en) | 2023-11-09 |
EP3925976A1 (en) | 2021-12-22 |
AU2021201494A1 (en) | 2021-03-25 |
RU2020112333A (ru) | 2021-10-08 |
JP2023166409A (ja) | 2023-11-21 |
MX2020002626A (es) | 2020-10-07 |
EP3679071A1 (en) | 2020-07-15 |
CN111315782A (zh) | 2020-06-19 |
US20200277383A1 (en) | 2020-09-03 |
CA3112984A1 (en) | 2019-03-14 |
JP2021098733A (ja) | 2021-07-01 |
WO2019051308A1 (en) | 2019-03-14 |
AU2018329937A1 (en) | 2020-03-19 |
JP7431392B2 (ja) | 2024-02-15 |
KR20210030503A (ko) | 2021-03-17 |
IL281323A (en) | 2021-04-29 |
SG10202102502VA (en) | 2021-04-29 |
EP3679071A4 (en) | 2021-06-09 |
RU2021110369A (ru) | 2021-06-01 |
CN113004417A (zh) | 2021-06-22 |
CA3074840A1 (en) | 2019-03-14 |
JP2020533311A (ja) | 2020-11-19 |
BR112020004489A2 (pt) | 2020-09-08 |
IL273067A (en) | 2020-04-30 |
SG11202001930QA (en) | 2020-04-29 |
US20210292420A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
AU2020267226B2 (en) | Multispecific binding proteins targeting nkg2d, cd16. and trop2 | |
MX2021002969A (es) | Proteinas de union a nkg2d, cd16, y egfr, ccr4 o pd-l1. | |
MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
MX2019013998A (es) | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). | |
EP4273258A3 (en) | Proteins binding her2, nkg2d and cd16 | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
MX2019009566A (es) | Proteinas de union a bcma, nkg2d y cd16. | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
GEP20227440B (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
MX2020002036A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado al tumor. | |
EP3585431A4 (en) | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES | |
PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
MX2019013995A (es) | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. | |
MX2020001257A (es) | Proteinas que se unen a nkg2d, cd16 y flt3. | |
MX2018002166A (es) | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso. | |
MX2020008333A (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. | |
WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
MX2019009943A (es) | Proteínas que se unen a gd2, nkg2d y cd16. | |
MX2019014000A (es) | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
MX2022004430A (es) | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). |